Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group

Salvi, SundeepSantosh; Ghorpade, Deesha; Dhoori, Sahajal; Dhar, Raja; Dumra, Harjit; Chhajed, PrashantN; Bhattacharya, Parathasarathi; Rajan, Sujeet; Talwar, Deepak; Christopher, DevasahayamJ; Mohan, Murali; Udwadia, Zarir

doi:10.4103/lungindia.lungindia_659_21

Cited by 8 publications

(9 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 33 ] Post-COVID-19 lung fibrosis has been given several names but the most accepted term is a post-COVID interstitial lung disease. [ 34 ] Several prospective cohort studies showed that the majority of these lung sequelae resolved without any use of antifibrotics. [ 35 36 ] There are a few similarities in lung fibrosis in COVID-19, IPF, and systemic sclerosis-related ILD.…”

Section: Q7 When and How Long Antifibrotic In Post-covid Pulmonary Fi...mentioning

confidence: 99%

“…[ 38 ] Although the expert group in one of the studies recommended antifibrotics in a patient with persistent symptoms, hypoxia, and fibrosis-like changes for 3 to 6 months. [ 34 ] Currently, a few trials of nintedanib and pirfenidone in post-COVID fibrosis are going on, which will provide insights into the efficacy of antifibrotics in preventing as well as treating fibrosis in moderate-to-severe COVID-19 patients. One study by Umemura et al .…”

Section: Q7 When and How Long Antifibrotic In Post-covid Pulmonary Fi...mentioning

confidence: 99%

See 1 more Smart Citation

Antifibrotic in interstitial lung diseases

Rai¹,

Tripathi²

2022

Lung India

View full text Add to dashboard Cite

Section: Q7 When and How Long Antifibrotic In Post-covid Pulmonary Fi...mentioning

confidence: 99%

Section: Q7 When and How Long Antifibrotic In Post-covid Pulmonary Fi...mentioning

confidence: 99%

Antifibrotic in interstitial lung diseases

Rai¹,

Tripathi²

2022

Lung India

View full text Add to dashboard Cite

“…The phrase "post-COVID-19 pulmonary fibrosis" has been criticised by an expert working committee because it implies a "permanent" nature, which the majority of people with fibrotic lung disease after COVID-19 do not have. ILD post-COVID-19 is a better expression to use (23) . It is not known for sure how long antifibrotic medications should be taken.…”

Section: Table (2)mentioning

confidence: 99%

Efficacy of Pirfenidone as Antifibrotic Agent in Patients with Post Covid Fibrosis

Ibrahim

Elshahaat²,

Anwar³

2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Backkground: Due to repeated respiratory infections induced by the coronavirus, pulmonary fibrosis develops over time. Life's quality is negatively impacted. Pirfenidone may be essential in avoiding serious lung problems because it has anti-fibrotic properties. Objective: This study aimed at prevention of the damage produced by post covid-19 fibrosis and avoiding long term complications. Methods: This study enrolled 50 adult patients with post covid fibrosis without chest diseases history, who were randomly chosen from Chest Outpatient Clinic, Zagazig University. They were divided into 2 groups. One group received pirfenidone and prednisolone and the other received prednisolone. Demographics and laboratory parameters were evaluated. Forced vital capacity (FVC), baseline oxygen saturation (SpO2), 6-minute walk distance test (6MWT), King's brief interstitial lung diseases (K-BILD) and CT severity score (CSS) were performed at the first visit, after one and three months. Results: Each group included 25 patients with a mean age of 47.1 ± 8.7 and 49.3 ± 13.7 years. There were statistically non-significant differences between both groups as regards age, sex, comorbidities and period from acute infection of COVID-19. At the first visit, there were statistically non-significant differences as regards FVC, SpO2, 6MWT, K-BILD and CSS. There were statistically significant differences as regards K-BILD and CSS and highly significant as regards 6MWT after one month of treatment. After 3 months, there were highly statistically significant differences as regards all parameters, which were all higher among pirfenidone + prednisolone group. Conclusion: Antifibrotic medications as pirfenidone can reduce fibrotic changes and enhance patients' quality of life who have post-COVID-19 fibrosis.

show abstract

“…In the article titled “Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group”, published on pages 177-186, Issue 2, Volume 39 of Lung India[ 1 ], the third author’s name is incorrectly written as “Sahajal Dhoori.” The correct author’s name should read as “Sahajal Dhooria.”…”

mentioning

confidence: 99%

Erratum: Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group

2022

Lung India

View full text Add to dashboard Cite

Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group

Cited by 8 publications

References 64 publications

Antifibrotic in interstitial lung diseases

Antifibrotic in interstitial lung diseases

Efficacy of Pirfenidone as Antifibrotic Agent in Patients with Post Covid Fibrosis

Erratum: Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group

Contact Info

Product

Resources

About